New Search

Advanced search
Export article
Open Access

KEYNOTE‐032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non‐Small Cell Lung Cancer

Yuxiang Ma, Wenfeng Fang, Yang Zhang, Yunpeng Yang, Shaodong Hong, Yuanyuan Zhao, Shuang Xie, Jun Ge, Haojin Zhou, Hongyun Zhao, Li Zhang
Published: 5 March 2020
 by  Wiley
The Oncologist , Volume 25; doi:10.1634/theoncologist.2020-0067

Abstract: Lessons Learned Results of the KEYNOTE‐032 study showed that the safety and pharmacokinetic profiles of pembrolizumab in Chinese patients were comparable with those observed in international studies, and antitumor activity was encouraging. These data support further evaluation of pembrolizumab to improve clinical outcomes in Chinese patients with advanced non‐small cell lung cancer. Background The KEYNOTE‐032 study evaluated pembrolizumab pharmacokinetics and clinical outcomes in Chinese patients with locally advanced and/or metastatic non‐small‐cell lung cancer (NSCLC) and prior treatment failure and/or ineligibility for standard therapy. Methods Patients were randomized 1:1:1 to pembrolizumab 2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks (up to 35 cycles). Safety and pharmacokinetics were primary endpoints; antitumor activity was a secondary endpoint. Results A total of 42 of 44 randomized patients received pembrolizumab treatment (2 mg/kg, n = 14; 10 mg/kg, n = 13; 200 mg, n = 15). Treatment‐related adverse events (AEs) occurred in 29 of 42 (69%) patients (grade 3–4, 4/42 [10%]); 5 (12%) had immune‐mediated AEs and infusion reactions. Pembrolizumab single dose half‐life following 2 mg/kg, 10 mg/kg, and 200 mg was 15.1, 15.8, and 12.3 days, respectively. Serum exposure at the doses studied (range, 2–10 mg/kg) was approximately linear; steady‐state area under the curve0–21 days (95% confidence interval [CI]) was 730.9 (627.4–851.6), 2,819.2 (2,009.4–3,955.4), and 931.0 (724.4–1,196.6) μg•day/mL, respectively. After 7.9 (range, 0.7–13.1) months median follow‐up overall, objective response rate was 14.3% (95% CI, 5.4%–28.5%); median progression‐free survival was 2.1 (95% CI, 2.1–4.2) months, and median overall survival was not reached (95% CI, 6.6 months–not reached). Conclusion Pembrolizumab had manageable toxicity, linear serum exposure, and encouraging antitumor activity in Chinese patients with advanced NSCLC.
Keywords: safety / pharmacokinetics / Lung / Treatment / survival / antitumor / Pembrolizumab / Chinese patients / KEYNOTE / Mg/kg

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "The Oncologist" .
References (15)
    Back to Top Top